Investing.com - Mink Therapeutics (NASDAQ: INKT) reported first quarter EPS of $0.23, $0.44 better than the analyst estimate of $-0.21. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Mink Therapeutics's stock price closed at $2.08. It is down -12.97% in the last 3 months and down -23.08% in the last 12 months.
Mink Therapeutics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Mink Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Mink Therapeutics's Financial Health score is "weak performance".
Check out Mink Therapeutics's recent earnings performance, and Mink Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar